Pre-order Enquiry
Request Free Sample
Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028
SKU ID : DEL-14679804 | Publishing Date : 01-Sep-2019 | No. of pages : 160
Detailed TOC of Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028
1. Key Insights2. Hepatic Encephalopathy Market Overview at a Glance
2.1. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2017
2.2. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2028
3. Hepatic Encephalopathy (HE): Disease Background and Overview
3.1. Introduction
3.2. Classification of Hepatic Encephalopathy
3.3. Symptoms of Hepatic Encephalopathy
3.4. Cause and risk factors of Hepatic Encephalopathy
3.5. Pathophysiology
3.6. Pathogenesis of Hepatic Encephalopathy
3.7. Diagnosis
3.8. The differential diagnosis for Hepatic Encephalopathy
3.9. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Methodology
4.3. 7MM Total Prevalent Patient Population of Hepatic Encephalopathy
4.4. 7MM Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy
5. Country Wise-Epidemiology of Hepatic Encephalopathy
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Hepatic Encephalopathy in the United States
5.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States
5.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
5.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
5.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Hepatic Encephalopathy in Germany
5.2.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany
5.2.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
5.2.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
5.2.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Hepatic Encephalopathy in France
5.2.2.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France
5.2.2.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
5.2.2.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
5.2.2.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Hepatic Encephalopathy in Italy
5.2.3.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy
5.2.3.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
5.2.3.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
5.2.3.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Hepatic Encephalopathy in Spain
5.2.4.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain
5.2.4.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
5.2.4.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
5.2.4.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
5.2.5.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
5.2.5.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
5.2.5.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
5.2.5.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
6. Japan Epidemiology
6.1. Assumptions and Rationale
6.2. Total Prevalent Cases of Hepatic Encephalopathy in Japan
6.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan
6.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
6.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
6.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
7. Treatment and Management of Hepatic Encephalopathy
7.1. Line of therapies for the treatment of Hepatic Encephalopathy
7.2. Treatment algorithm
7.3. Treatment Guideline
7.3.1. Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
7.3.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
8. Unmet Needs
9. Marketed Drugs
9.1. Xifaxan: Salix Pharmaceuticals
9.1.1. Product Description
9.1.2. Regulatory Milestones
9.1.3. Research and Development
9.1.4. Clinical Trials Information
9.1.5. Product Profile
10. Emerging Drugs
10.1. Key Cross Competition
10.2. SYNB1020: Synlogic
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Product Profile
10.3. GR3027: Umecrine Cognition
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. MNK-6105/ MNK-6106: Mallinckrodt Therapeutics
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Product Profile
11. Hepatic Encephalopathy: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Hepatic Encephalopathy in the 7MM
11.3. Market Size of Hepatic Encephalopathy by Therapies in the 7MM
12. Market Outlook: The United States
12.1. United States Market Size
12.1.1. The total Market size of Hepatic Encephalopathy
12.1.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
13. Market Outlook: Europe
13.1. Germany
13.1.1. Total Market size of Hepatic Encephalopathy
13.1.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
13.2. France
13.2.1. Total Market size of Hepatic Encephalopathy
13.2.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
13.3. Italy
13.3.1. Total Market size of Hepatic Encephalopathy
13.3.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
13.4. Spain
13.4.1. Total Market size of Hepatic Encephalopathy
13.4.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
13.5. United Kingdom
13.5.1. Total Market size of Hepatic Encephalopathy
13.5.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
14. Market Outlook: Japan
14.1. Total Market size of Hepatic Encephalopathy
14.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
15. Market Drivers
16. Market Barriers
17. Appendix
17.1. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Figures, Tables and Charts Available in Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028
Table 1 Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline 2014Table 2 West Haven Criteria for hepatic encephalopathy and symptoms
Table 3 Stages of Hepatic Encephalopathy (HE)
Table 4 Total Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
Table 5 Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
Table 6 Total Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
Table 7 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
Table 8 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Table 9 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Table 10 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Table 11 Total Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
Table 12 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
Table 13 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Table 14 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Table 15 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Table 16 Total Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
Table 17 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
Table 18 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Table 19 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Table 20 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Table 21 Total Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
Table 22 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
Table 23 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Table 24 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Table 25 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Table 26 Total Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
Table 27 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
Table 28 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Table 29 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Table 30 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Table 31 Total Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Table 32 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Table 33 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Table 34 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Table 35 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Table 36 Total Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
Table 37 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
Table 38 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Table 39 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Table 40 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Table 41 Common Treatment Options for Hepatic Encephalopathy
Table 42 Treatment Summary
Table 43 Rifaximin, Clinical Trial Description, 2019
Table 44 List of Few Emerging Drugs Analysis
Table 45 SYNB1020, Clinical Trial Description, 2019
Table 46 MNK6106, Clinical Trial Description, 2019
Table 47 Market size of Hepatic Encephalopathy by Region in USD Million (2017–2028)
Table 48 Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in 7MM, in USD Million (2017-2028)
Table 49 United States Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 50 The US Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 51 Germany Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 52 Germany Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 53 France Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 54 France Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 55 Italy Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 56 Italy Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 57 Spain Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 58 Spain Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 59 United Kingdom Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 60 The UK Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Table 61 Japan Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Table 62 Japan Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 1 Symptoms of Hepatic Encephalopathy
Figure 2 Grading of the symptoms of Hepatic Encephalopathy
Figure 3 Symptoms of Hepatic Encephalopathy
Figure 4 Pathophysiology of hepatic encephalopathy
Figure 5 Pathophysiology of hepatic encephalopathy
Figure 6 Ammonia trafficking in hepatic encephalopathy (HE) from an organism (left panel) and an organ (right panel) perspective
Figure 7 The classification of HE, adapted from Amodio et al.
Figure 8 Total Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
Figure 9 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
Figure 10 Total Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
Figure 11 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
Figure 12 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Figure 13 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Figure 14 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
Figure 15 Total Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
Figure 16 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
Figure 17 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Figure 18 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Figure 19 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
Figure 20 Total Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
Figure 21 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
Figure 22 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Figure 23 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Figure 24 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
Figure 25 Total Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
Figure 26 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
Figure 27 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Figure 28 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Figure 29 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
Figure 30 Total Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
Figure 31 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
Figure 32 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Figure 33 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Figure 34 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
Figure 35 Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Figure 36 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Figure 37 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Figure 38 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Figure 39 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
Figure 40 Total Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
Figure 41 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
Figure 42 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Figure 43 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Figure 44 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
Figure 45 Management of patients with hepatic encephalopathy (HE)
Figure 46 Treatment algorithm for patients with minimal HE
Figure 47 Treatment algorithm for patients with minimal HE
Figure 48 Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
Figure 49 Unmet Needs
Figure 50 Market size of Hepatic Encephalopathy by Region in USD Million (2017–2028)
Figure 51 Market Size of Hepatic Encephalopathy by Therapies in the Seven Major Market (7MM), in USD Million (2017–2028)
Figure 52 United States Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 53 The US Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 54 Germany Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 55 Germany Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 56 France Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 57 France Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 58 Italy Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 59 Italy Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 60 Spain Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 61 Spain Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 62 United Kingdom Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 63 The UK Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 64 Japan Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
Figure 65 Japan Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
Figure 66 Market Drivers
Figure 67 Market Barriers
Keyplayers in Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028
Salix PharmaceuticalsSynlogic
Umecrine Cognition
Mallinckrodt Therapeutics
Request Sample
Request Discount
